



NEONATAL MEDICATION GUIDELINE					
Midazolam					
Scope (Staff): Nursing, Medical and Pharmacy Staff					
Scope (Area):	KEMH NICU, PCH NICU, NETS WA				
This document should be read in conjunction with the Disclaimer .					

Quick Links

Side Effects & Interactions **Preparation & Monitoring** Dose Administration

Restrictions

Formulary: Restricted

Requires Neonatologist review within 24 hours of initiation

HIGH RISK Medication 1



Description

Short acting benzodiazepine

Presentation

5mg/5mL (1000 microgram/mL) Ampoule:

15mg/3mL (5000 microgram/mL)

Oral liquid: 2.5mg/mL (2500 microgram/mL)

Storage

Store at room temperature, below 25°C

Protect from light

Schedule 4 Restricted Medication

Indications

Short acting sleep-inducing agent for:

Short procedures

- Induction of anaesthesia
- Prolonged sedation of ventilated patients

Treatment for refractory seizures

Midazolam enhances the central sedative effects of tranquilisers, narcotics, analgesics, and anaesthetics

Dose

IV:

Intermittent dosing:

50 – 150 microgram/kg/dose every 2 – 4 hours as required followed by a continuous infusion

Continuous infusion – SEDATION

0.5 - 1 microgram/kg/minute

<u>Continuous infusion – SEIZURES</u>

1 – 7 microgram/kg/minute

Induction/Sedation

Oral:

250 – 500 microgram/kg/dose administered 15 – 30 minutes before a procedure

Dose Adjustment

Dose adjusted according to response with adequate monitoring

Dose adjustment in seizure control may be higher – use with caution

Preparation

<u>IV</u>

Available from CIVAS (KEMH & PCH)

Infusion calculation:

Dilute 3mg of midazolam per kilogram of baby's weight and make to a final volume of 50mL with a compatible fluid

Concentration = 1 microgram/kg/minute = 1 mL/hour

Administration

<u>Oral</u>

May be given at any time with regards to feeds

IV

Inject over at least 5 minutes

IV infusion

Infuse at the prescribed rate using a controlled infusion pump

Compatible Fluids

Sodium chloride 0.9%, Glucose 5%, Glucose 10%

Compatibility with Heparin

	Sodium Chloride 0.9%	Glucose 5%	Glucose 10%
WITH Heparin	24 hours at room temperature	24 hours at room temperature	No information
WITHOUT Heparin	48 hours at room temperature	48 hours at room temperature	24 hours at room temperature

Y-Site Compatibility

Refer to KEMH Neonatal Medication Guideline: Y-Site IV Compatibility in Neonates

Side Effects

Common: hypotension, reduced cardiac output

Serious: apnoea, respiratory depression, seizures

Interactions

Combination use with other CNS depressants can increase the opioid effect – increasing risk of respiratory depression and sedation

Concurrent administration with erythromycin promotes accumulation

Pentoxifylline may decrease the anaesthetic/sedative effect of benzodiazepines

Care needs to be taken with adding or withdrawing caffeine

Comments

May be used in conjunction with morphine

Flumazenil (see monograph) is used as the reversal agent for midazolam

Related Policies, Procedures & Guidelines

CAHS Clinical Practice Guidelines:

Neonatal Seizures

End of Life Care

Resuscitation and Intubation Drugs for Neonates

Calculation of the Composition of Drug Infusions

Medication Administration: Intramuscular, Subcutaneous, Intravascular

References

Truven Health Analytics. Midazolam. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2020 Sep 4]. Available from: https://neofax.micromedexsolutions.com/

Neomed Formularies. Midazolam. In: The Royal Hospital for Women [Internet]. [South Eastern Sydney, New South Wales; 2017 [cited 2020 Sep 4]. Available from:

https://www.seslhd.health.nsw.gov.au/royal-hospital-for-women/neomed-formularies

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2019. P1356.

British National Formulary. BNF for Children. 2018-19 ed. London, UK: BMJ Group and Pharmaceutical Press; 2018. p. 223-224

Kemp AC, McDowell JM. Paediatric Pharmacopoeia. 13th edition. Parkville, IVC: Royal Children's Hospital Pharmacy Department; 2002. p. 175

Keywords	Midazolam, seizures, induction						
Document Owner:	Head of Department - Neonatology						
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate						
Version Info:	Updated template, amended links, updated compatibility table						
Date First Issued:	March 2003	Last Reviewed:	03/10/2020		Review Date:	03/10/2023	
Endorsed by:	Neonatal Directorate Management Group				Date:	September 2020	
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care			
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety			
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management			
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration			
Printed or personally saved electronic copies of this document are considered uncontrolled.							
Access the current version from WNHS HealthPoint.							

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.